Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-α and melphalan

Annals of Surgical Oncology

Volumn 9, Issue 4, 2002, Pages 355-363

  Van Ginkel, Robert J ^a   Limburg, Pieter C ^a   Piers, D Albertus ^a   Koops, Heimen Schraffordt ^a   Hoekstra, Harald J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Hyperthermic isolated limb perfusion; Iodine 131 labeled human serum albumin; Leakage; Melanoma; Sarcoma; Tumor necrosis factor

Indexed keywords

BILIRUBIN; C REACTIVE PROTEIN; CHOLESTEROL; GAMMA INTERFERON; INTERLEUKIN 6; MELPHALAN; SERUM ALBUMIN I 131; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; AXILLARY ARTERY; CANCER COMBINATION CHEMOTHERAPY; CAPILLARY LEAK SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG DELIVERY SYSTEM; FEMALE; FEMORAL ARTERY; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPOCHOLESTEROLEMIA; LEUKOCYTE COUNT; LIMB PERFUSION; MALE; MELANOMA; METASTASIS; MONITORING; POPLITEAL ARTERY; PROTEIN BLOOD LEVEL; SOFT TISSUE SARCOMA; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; HUMANS; HYPOTHERMIA, INDUCED; IODINE RADIOISOTOPES; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; MONITORING, PHYSIOLOGIC; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SARCOMA; SERUM ALBUMIN; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036256282     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/aso.2002.9.4.355     Document Type: Article

References (28)

1. Chemotherapy of cancer: Regional perfusion utilizing an extra-corporeal circuit
2. Hyperthermic perfusion with chemotherapy for cancers of the extremities
3. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial
4. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
5. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial
6. High serum levels of TNF-alpha after its administration for isolation perfusion of the limb
7. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs
8. The leakage factor in regional perfusion with chemotherapeutic agents
9. Rapid measurement of blood leakage during regional chemotherapy
10. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma
11. Continuous monitoring of leakage during regional perfusion
12. A modified dye dilution method to estimate leakage during regional isolated perfusion of the extremity
13. The use of a hand-held gamma detector improves the safety of isolated limb perfusion
14. Leakage measurement during selective limb perfusion using a gamma probe
15. Isolated regional perfusion in malignant melanoma of the extremities
16. Improved tissue perfusion during pressure regulated regional perfusion: A clinical study
17. Dosimetry in isolation perfusion of the limb by assessment of perfused tissue volume and grading of toxic tissue reactions
18. Prevention of neural and muscular lesions during hyperthermic regional perfusion
19. Endotoxins and cytokines during liver transplantation: Changes in plasma levels and effects on clinical outcome
20. Nonparametric estimates from incomplete observations
21. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage
22. Systemic leakage during isolated limb perfusion for melanoma
23. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan
24. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment
25. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan
26. Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs
27. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan